101 related articles for article (PubMed ID: 24640092)
1. Tumor associated proteases -- prognostic markers of colorectal cancer.
Gershtein ES; Korotkova EA; Prorokov VV; Kushlinskii NE
Klin Lab Diagn; 2013 Oct; (10):43-7, 5-10. PubMed ID: 24640092
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of tumor-associated proteases in colorectal cancer.
Kushlinskii NE; Gershtein ES; Korotkova EA; Prorokov VV
Bull Exp Biol Med; 2013 Jan; 154(3):365-9. PubMed ID: 23484202
[TBL] [Abstract][Full Text] [Related]
3. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
4. [Clinical prospects of tumor-associated proteases and their tissue inhibitors investigation in oncologic patient].
Gershteĭn ES; Kushlinskiĭ NE
Vestn Ross Akad Med Nauk; 2013; (5):16-27. PubMed ID: 24000664
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.
Hilska M; Roberts PJ; Collan YU; Laine VJ; Kössi J; Hirsimäki P; Rahkonen O; Laato M
Int J Cancer; 2007 Aug; 121(4):714-23. PubMed ID: 17455256
[TBL] [Abstract][Full Text] [Related]
6. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology.
Baker EA; Leaper DJ
Eur J Cancer; 2003 May; 39(7):981-8. PubMed ID: 12706368
[TBL] [Abstract][Full Text] [Related]
7. Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation.
Badier-Commander C; Verbeuren T; Lebard C; Michel JB; Jacob MP
J Pathol; 2000 Sep; 192(1):105-12. PubMed ID: 10951407
[TBL] [Abstract][Full Text] [Related]
8. mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay.
Ramón L; Gilabert-Estellés J; Castelló R; Gilabert J; España F; Romeu A; Chirivella M; Aznar J; Estellés A
Hum Reprod; 2005 Jan; 20(1):272-8. PubMed ID: 15579491
[TBL] [Abstract][Full Text] [Related]
9. Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer.
Kushlinskii NE; Gershtein ES; Ivannikov AA; Davydov MM; Chang VL; Ognerubov NA; Stilidi IS
Bull Exp Biol Med; 2019 Jan; 166(3):373-376. PubMed ID: 30627896
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
Baker EA; Bergin FG; Leaper DJ
Mol Pathol; 2000 Dec; 53(6):307-12. PubMed ID: 11193049
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients.
Groblewska M; Mroczko B; Gryko M; Kędra B; Szmitkowski M
Folia Histochem Cytobiol; 2010 Dec; 48(4):564-71. PubMed ID: 21478099
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.
Curran S; Dundas SR; Buxton J; Leeman MF; Ramsay R; Murray GI
Clin Cancer Res; 2004 Dec; 10(24):8229-34. PubMed ID: 15623598
[TBL] [Abstract][Full Text] [Related]
14. The role of cysteine and serine proteases in colorectal carcinoma.
Herszènyi L; Plebani M; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
Cancer; 1999 Oct; 86(7):1135-42. PubMed ID: 10506696
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer.
Morán A; Iniesta P; García-Aranda C; De Juan C; Díaz-López A; Sánchez-Pernaute A; Torres AJ; Díaz-Rubio E; Balibrea JL; Benito M
Oncol Rep; 2005 Jan; 13(1):115-20. PubMed ID: 15583811
[TBL] [Abstract][Full Text] [Related]
16. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
Manenti L; Paganoni P; Floriani I; Landoni F; Torri V; Buda A; Taraboletti G; Labianca R; Belotti D; Giavazzi R
Eur J Cancer; 2003 Sep; 39(13):1948-56. PubMed ID: 12932675
[TBL] [Abstract][Full Text] [Related]
17. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients.
Waas ET; Hendriks T; Lomme RM; Wobbes T
Dis Colon Rectum; 2005 Apr; 48(4):700-10. PubMed ID: 15906450
[TBL] [Abstract][Full Text] [Related]
18. The effect of IL-1alpha on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in osteoblastic ROS 17/2.8 cells.
Fujisaki K; Tanabe N; Suzuki N; Mitsui N; Oka H; Ito K; Maeno M
Life Sci; 2006 Mar; 78(17):1975-82. PubMed ID: 16313928
[TBL] [Abstract][Full Text] [Related]
19. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
20. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
Buø L; Meling GI; Karlsrud TS; Johansen HT; Aasen AO
Hum Pathol; 1995 Oct; 26(10):1133-8. PubMed ID: 7557947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
